NCT00857545

Phase II Randomized Study of Immunological Adjuvant OPT-821 With Versus Without Polyvalent Antigen-KLH Conjugate Vaccine in Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer in Second or Third Complete Clinical

Condition: Ovarian Cancer 

Sponsor: Gynecologic Oncology Group 

Phase: 2

NCT02980198

A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis

Condition: Dermatomyositis
Sponsor: Neovacs
Phase 2 

NCT02947854

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Condition: Healthy Volunteers
Sponsor: PCI Biotech
Phase 1 

NCT02745756

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Conditions: Neuroblastoma, Nerve Tissue Neoplasms
Sponsor: H. Lee Moffitt Cancer Center & Research Institute
Collaborator: All Childrens Hosp Johns HopkinsMedicine 
Phase 1 

NCT02665364

Study of IFN-K in Systemic Lupus Erythematosus

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Sponsor: Neovacs
Phase 2 

NCT02579252

24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer's Disease (ADAMANT)

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase 2 

NCT02543749

DC Vaccination in CML

Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Sponsor: Charite University, Berlin, Germany
Phase 1
Phase 2  

NCT02508896

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (AFF012)

A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE® Vaccines in Healthy Subjects

Condition: Hypercholesterolemia
Sponsor: Affiris AG
Collaborator: Medical University of Vienna
Phase 1
 

NCT02455557

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 2 

NCT02334865

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Conditions: Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 1